WO2022231374A1 - 약물을 함유하고 양친성 고분자를 포함하지 않는 나노입자 제조용 키트 - Google Patents
약물을 함유하고 양친성 고분자를 포함하지 않는 나노입자 제조용 키트 Download PDFInfo
- Publication number
- WO2022231374A1 WO2022231374A1 PCT/KR2022/006174 KR2022006174W WO2022231374A1 WO 2022231374 A1 WO2022231374 A1 WO 2022231374A1 KR 2022006174 W KR2022006174 W KR 2022006174W WO 2022231374 A1 WO2022231374 A1 WO 2022231374A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- kit
- nanoparticles
- chamber
- containing nanoparticles
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 145
- 229940079593 drug Drugs 0.000 title claims abstract description 94
- 239000003814 drug Substances 0.000 title claims abstract description 94
- 229920000642 polymer Polymers 0.000 title claims abstract description 14
- 150000001767 cationic compounds Chemical class 0.000 claims abstract description 30
- 239000000203 mixture Substances 0.000 claims description 27
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 23
- 239000004626 polylactic acid Substances 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 15
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 239000002738 chelating agent Substances 0.000 claims description 7
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 7
- 239000003002 pH adjusting agent Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 abstract description 26
- 238000012377 drug delivery Methods 0.000 abstract description 5
- 239000000470 constituent Substances 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 description 75
- 239000000243 solution Substances 0.000 description 41
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 24
- -1 cationic lipid Chemical class 0.000 description 24
- 239000002245 particle Substances 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 235000012000 cholesterol Nutrition 0.000 description 14
- 229920001577 copolymer Polymers 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000011734 sodium Substances 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 239000011732 tocopherol Substances 0.000 description 10
- 229960001295 tocopherol Drugs 0.000 description 9
- 229930003799 tocopherol Natural products 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 8
- 235000010384 tocopherol Nutrition 0.000 description 8
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000002296 dynamic light scattering Methods 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 5
- 229920002873 Polyethylenimine Polymers 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 4
- WQTCTMDKQPZJES-UHFFFAOYSA-N 2-aminoethyl dihydrogen phosphate;nonane Chemical compound NCCOP(O)(O)=O.CCCCCCCCC.CCCCCCCCC WQTCTMDKQPZJES-UHFFFAOYSA-N 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000007974 sodium acetate buffer Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000003260 vortexing Methods 0.000 description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 3
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 229920006317 cationic polymer Polymers 0.000 description 3
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000009881 electrostatic interaction Effects 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229960002510 mandelic acid Drugs 0.000 description 3
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229940038309 personalized vaccine Drugs 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- PGPMCWZMPPZJML-NAFNZUQFSA-N 1,2-di-[(9Z)-hexadecenoyl]-sn-glycero-3-phosphoethanolamine Chemical compound CCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCC PGPMCWZMPPZJML-NAFNZUQFSA-N 0.000 description 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 2
- GPWHCUUIQMGELX-VHQDNGOZSA-N 1,2-dipalmitoleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCC GPWHCUUIQMGELX-VHQDNGOZSA-N 0.000 description 2
- FHQVHHIBKUMWTI-ZCXUNETKSA-N 1-palmitoyl-2-oleoyl phosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC FHQVHHIBKUMWTI-ZCXUNETKSA-N 0.000 description 2
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 2
- TXLHNFOLHRXMAU-UHFFFAOYSA-N 2-(4-benzylphenoxy)-n,n-diethylethanamine;hydron;chloride Chemical compound Cl.C1=CC(OCCN(CC)CC)=CC=C1CC1=CC=CC=C1 TXLHNFOLHRXMAU-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 2
- ZLGYVWRJIZPQMM-HHHXNRCGSA-N 2-azaniumylethyl [(2r)-2,3-di(dodecanoyloxy)propyl] phosphate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCC ZLGYVWRJIZPQMM-HHHXNRCGSA-N 0.000 description 2
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940124447 delivery agent Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 125000005645 linoleyl group Chemical group 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- GLGLUQVVDHRLQK-WRBBJXAJSA-N n,n-dimethyl-2,3-bis[(z)-octadec-9-enoxy]propan-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/CCCCCCCC GLGLUQVVDHRLQK-WRBBJXAJSA-N 0.000 description 2
- 244000309459 oncolytic virus Species 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 2
- 229920000962 poly(amidoamine) Polymers 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 108010011110 polyarginine Proteins 0.000 description 2
- 229920002851 polycationic polymer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940048914 protamine Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- NRWCNEBHECBWRJ-UHFFFAOYSA-M trimethyl(propyl)azanium;chloride Chemical compound [Cl-].CCC[N+](C)(C)C NRWCNEBHECBWRJ-UHFFFAOYSA-M 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 101150079396 trpC2 gene Proteins 0.000 description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OPVZUEPSMJNLOM-ZCXUNETKSA-N (1-hexadecanoyloxy-3-phosphonooxypropan-2-yl) (z)-octadec-9-enoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC OPVZUEPSMJNLOM-ZCXUNETKSA-N 0.000 description 1
- OKLASJZQBDJAPH-UHFFFAOYSA-N (2-dodecanoyloxy-3-phosphonooxypropyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCCCCCC OKLASJZQBDJAPH-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- VKQJCYCXUGUKQJ-MAZCIEHSSA-N (9Z,12Z)-N-[2-[2-[2-[2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]ethylamino]ethylamino]ethylamino]ethyl]octadeca-9,12-dienamide Chemical compound N(CCNCCNC(CCCCCCC\C=C/C\C=C/CCCCC)=O)CCNCCNC(CCCCCCC\C=C/C\C=C/CCCCC)=O VKQJCYCXUGUKQJ-MAZCIEHSSA-N 0.000 description 1
- ZGAFPTGELYKMAW-CLFAGFIQSA-N (Z)-N-[2-[2-[2-[2-[2-[[(Z)-octadec-9-enoyl]amino]ethylamino]ethylamino]ethylamino]ethylamino]ethyl]octadec-9-enamide Chemical compound C(CNCCNCCNCCNCCNC(CCCCCCC\C=C/CCCCCCCC)=O)NC(CCCCCCC\C=C/CCCCCCCC)=O ZGAFPTGELYKMAW-CLFAGFIQSA-N 0.000 description 1
- GCAONVVVMAVFDE-NADBREJJSA-N (z)-n-[(e)-octadec-9-enyl]octadec-9-enamide Chemical compound CCCCCCCC\C=C\CCCCCCCCNC(=O)CCCCCCC\C=C/CCCCCCCC GCAONVVVMAVFDE-NADBREJJSA-N 0.000 description 1
- DKHSZSKSPXFGPM-HWAYABPNSA-N (z)-n-[2-[2-[[(z)-tetradec-9-enoyl]amino]ethylamino]ethyl]tetradec-9-enamide Chemical compound CCCC\C=C/CCCCCCCC(=O)NCCNCCNC(=O)CCCCCCC\C=C/CCCC DKHSZSKSPXFGPM-HWAYABPNSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 1
- IJFVSSZAOYLHEE-SSEXGKCCSA-N 1,2-dilauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-N 0.000 description 1
- YFWHNAWEOZTIPI-DIPNUNPCSA-N 1,2-dioctadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCCCC YFWHNAWEOZTIPI-DIPNUNPCSA-N 0.000 description 1
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- JFBCSFJKETUREV-LJAQVGFWSA-N 1,2-ditetradecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCCC JFBCSFJKETUREV-LJAQVGFWSA-N 0.000 description 1
- OZSITQMWYBNPMW-GDLZYMKVSA-N 1,2-ditetradecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCC OZSITQMWYBNPMW-GDLZYMKVSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000846102 Mus musculus Short transient receptor potential channel 2 Proteins 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920001363 Polidocanol Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
- OBXRDFNCKFWKNY-MAZCIEHSSA-N [2-[(9z,12z)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC OBXRDFNCKFWKNY-MAZCIEHSSA-N 0.000 description 1
- SSCDRSKJTAQNNB-WVZYQCMWSA-N [3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC SSCDRSKJTAQNNB-WVZYQCMWSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 125000004097 arachidonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 229920000359 diblock copolymer Polymers 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- UAKOZKUVZRMOFN-JDVCJPALSA-M dimethyl-bis[(z)-octadec-9-enyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)CCCCCCCC\C=C/CCCCCCCC UAKOZKUVZRMOFN-JDVCJPALSA-M 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PZZHMLOHNYWKIK-UHFFFAOYSA-N eddha Chemical compound C=1C=CC=C(O)C=1C(C(=O)O)NCCNC(C(O)=O)C1=CC=CC=C1O PZZHMLOHNYWKIK-UHFFFAOYSA-N 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229950006462 lauromacrogol 400 Drugs 0.000 description 1
- 125000002463 lignoceryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002479 lipoplex Substances 0.000 description 1
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
Definitions
- the present invention relates to a kit for producing nanoparticles containing a drug, and more specifically, as a kit component that does not contain an amphiphilic polymer, nanoparticles containing a cationic compound and a polylactate and a drug , preferably in a specific weight ratio, a drug can be easily contained in nanoparticles by simply mixing, and furthermore, a drug-containing nanometer designed to further increase the cell delivery efficiency of the drug compared to a kit containing an amphiphilic polymer It relates to a kit for making particles.
- the delivery system is largely divided into a viral delivery agent using adenovirus or retrovirus, etc. and a non-viral delivery agent using cationic lipids and cationic polymers.
- a viral carrier it is known that there are many problems in commercialization because it is exposed to risks such as non-specific immune reaction and the production process is complicated. Therefore, the recent research direction is in the direction of improving the shortcomings by using a non-viral carrier.
- the non-viral delivery system has advantages in that it has fewer side effects in terms of in vivo safety and a low production price in terms of economic feasibility.
- Non-viral carriers used for the delivery of nucleic acid substances are a complex (lipoplex) of a cationic lipid and a nucleic acid using a cationic lipid, and a complex (polyplex) of a polycationic polymer and a nucleic acid.
- cationic lipids or polycationic polymers have been studied in that they stabilize the anionic drug by forming a complex through electrostatic interaction with the anionic drug and increase intracellular delivery (De Paula D.) , Bentley MV, Mahato RI, Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting, RNA 13 (2007) 431-56; Gary DJ, Puri N, Won YY, Polymer-based siRNA delivery: Perspectives on the fundamental and phenomenological distinctions from polymer -based DNA delivery, J Control release 121 (2007) 64-73).
- Nanoparticles including drugs often lose stability easily depending on the storage environment, so they are vulnerable to long-term storage and there is a risk that the quality may be damaged during transportation. In addition, it is very difficult to manufacture because it requires a complicated manufacturing process to ensure sufficient stability. Therefore, there is a demand for the development of a composition for drug delivery that is not significantly affected by the storage environment, is easy to use by the end consumer, and can further increase the cell delivery efficiency of the drug.
- the drug can be easily contained in the nanoparticles by simply mixing the kit components, which makes it easy for the end consumer to use.
- the drug-containing nanoparticles can be prepared easily and quickly just before use, so that the drug can be effectively delivered to the body without being affected by the storage or transport environment, and furthermore, the drug's cells It is possible to further increase the transfer efficiency.
- the present invention provides a first chamber containing nanoparticles including a cationic compound and a polylactate; and a second chamber containing a drug, which is an active ingredient selected from nucleic acids, polypeptides, viruses, or combinations thereof;
- the drug-containing nanoparticles are for delivering the drug into cells.
- At least one selected from the group consisting of the first chamber and the second chamber further includes an additional solvent.
- the solvent is an aqueous solvent, a water-miscible solvent, or a mixture thereof.
- the second chamber further includes one or more additives selected from a pH adjusting agent, an inorganic salt, a saccharide, a surfactant, a chelating agent, or a combination thereof.
- the drug-containing nanoparticle preparation kit comprises: a drug, which is an active ingredient selected from nucleic acids, polypeptides, viruses, or a combination thereof; cationic compounds; polylactate; menstruum; and at least one additive selected from a pH adjuster, an inorganic salt, a sugar, a surfactant, a chelating agent, or a combination thereof.
- the amount of the polylactic acid salt may be 0.1 to 15 parts by weight based on 1 part by weight of the cationic compound.
- the amount of the polylactic acid salt may be 0.5 to 3 parts by weight based on 1 part by weight of the cationic compound.
- the cationic compound and the polylactic acid salt may be used in the preparation of nanoparticles in the form of a solution that has been filtered one or more times.
- the drug-containing nanoparticle manufacturing kit according to the present invention separates the drug and the nanoparticles in separate chambers, so it is not affected by the storage or transportation environment.
- Drug-containing nanoparticles can be rapidly produced by simply mixing the components in the chamber without going through a complicated process, for example, in a hospital, with a personalized vaccine or with mRNA in a pandemic situation. If only therapeutic mRNA is produced without process optimization, it can be administered to humans immediately by simple mixing with the nanoparticles presented in the present invention.
- the drug-containing nanoparticle preparation kit according to the present invention can further increase the cell delivery efficiency of the drug, compared to the kit containing the amphiphilic polymer.
- Example 1 is an agarose gel electrophoresis result of an experiment to confirm whether mRNA-containing nanoparticles are prepared by the kit method performed in Example A of the present invention.
- Figure 2 is a non-kit method (simple mixing) carried out in Example A of the present invention - agarose gel electrophoresis results of the experiment to confirm whether the preparation of the mRNA-containing nanoparticles.
- a kit for preparing drug-containing nanoparticles according to the present invention comprises: a first chamber containing nanoparticles including a cationic compound and polylactate; and a second chamber containing a drug which is an active ingredient selected from nucleic acids, polypeptides, viruses, or combinations thereof, and does not contain an amphiphilic polymer.
- the kit of the present invention is composed of two or more chambers, and the end user can easily prepare drug-containing nanoparticles by simply mixing the contents of the chambers.
- the term “simple mixing” can include all acts of "mixing”, and means that no specific conditions are attached to the act of mixing.
- the mixing may be performed by various methods such as dripping, stirring (vortexing), decanting, and the like, but is not limited thereto.
- 90% or more, 95% or more, or 99% or more of the theoretically formable amount of drug-containing nanoparticles are rapidly, for example, within 1 minute, within 30 seconds, or within 15 seconds.
- the cationic compound and polylactate form nanoparticles through electrostatic interaction, and the end user can form drug-containing nanoparticles by simply mixing the produced nanoparticles with a drug.
- the drug-containing nanoparticles prepared by the kit of the present invention may be in a form in which at least a portion of the drug is bound to the outside of the nanoparticles. This drug-containing nanoparticle structure improves the stability of the drug in blood or body fluids.
- nucleic acid may be, for example, DNA, RNA, siRNA, shRNA, miRNA, mRNA, aptamer, antisense oligonucleotide, or a combination thereof, but is not limited thereto.
- polypeptide includes a polypeptide sequence of an antibody or fragment thereof, a protein having activity in the body, such as a cytokine, a hormone or an analog thereof, or an antigen, an analog or a precursor thereof, and is recognized as an antigen through a series of processes in the body. It may mean a protein that can be
- the “virus” may be an oncolytic virus, for example, adenovirus, vaccinia virus, herpes simplex virus (HSV) and vesicular stomatitis virus (VSV) It may be one or more selected from the group consisting of .
- the oncolytic virus is an adenovirus.
- the adenovirus used in the embodiment of the present invention contains a luciferase gene, which can be confirmed through imaging.
- the virus can express several types of therapeutic genes in the body of an individual, and is not limited to a specific molecular weight, protein, bioactivity, or therapeutic field.
- the prophylactic virus can induce immunity in the body of a subject against a target disease.
- Nanoparticles containing a virus for disease prevention reduce the induction of immunity by the virus itself, can designate or expand target cells, and reduce the hyperimmune response to the virus upon re-administration, so that effective effects can be obtained by inoculating several times. has an advantage
- the particle size of the nanoparticles may be defined as a Z-average value, for example, 800 nm or less, 600 nm or less, 500 nm or less, 400 nm or less, 300 nm or less, 200 nm or less, or 180 nm or less. and may be 10 nm or more, 50 nm or more, or 100 nm or more.
- the particle size of the nanoparticles, defined as the Z-average value is, for example, 10-800 nm, 10-600 nm, 10-500 nm, 10-400 nm, 10-300 nm, 10 to 200 nm or from 10 to 180 nm.
- the “Z-average” may mean an average of hydrodynamic diameters of particle distributions measured using dynamic light scattering (DSL).
- the nanoparticles have a monodisperse particle distribution, and the polydispersity index may be, for example, 0.01 to 0.30, 0.05 to 0.25, or 0.1 to 0.2.
- the surface charge of the nanoparticles may be, for example, -40 mV or more, -30 mV or more, -20 mV or more, or -10 mV or more, and also 40 mV or less, 30 mV or less, 20 mV or less, or It may be 10 mV or less.
- the surface charge of the nanoparticles may be, for example, -40 to 40 mV, -30 to 30 mV, -20 to 20 mV, or -10 to 10 mV.
- the surface charge may be measured in an environment close to a biological environment, for example, may be measured in 8 to 12 mM HEPES buffer (pH 7.0 to 7.5).
- the drug is a nucleic acid
- one or more ends of the nucleic acid may be modified with one or more selected from the group consisting of cholesterol, tocopherol and fatty acids having 10 to 24 carbon atoms.
- the cholesterol, tocopherol and fatty acids having 10 to 24 carbon atoms include cholesterol, tocopherols and their respective analogs, derivatives, and metabolites.
- the drug is, based on the total weight of the drug-containing nanoparticles prepared by the kit of the present invention, for example, 30% by weight or less, 25% by weight or less, 20% by weight or less, 15% by weight or less, 10% by weight or less, or 5 wt% or less, and may also be 0.001 wt% or more, 0.01 wt% or more, 0.05 wt% or more, 0.1 wt% or more, 0.25 wt% or more, 0.5 wt% or more, or 1 wt% or more.
- the drug is, based on the total weight of the drug-containing nanoparticles, for example, 0.05 to 30% by weight, 0.1 to 25% by weight, 0.25 to 20% by weight, 0.5 to 15% by weight, 1 to 10% by weight, or 1 to 5% by weight. If the content of the drug is less than the above range based on the total weight of the drug-containing nanoparticles, the amount of nanoparticles used as a carrier is too large compared to the drug, so there may be side effects due to the nanoparticles as a carrier, exceeding the above range If it is, there is a risk that the size of the drug-containing nanoparticles is too large to decrease particle stability and increase the loss rate during filter sterilization.
- the drug-containing nanoparticles may comprise a virus 1x10 6 to 1x10 14 VP (Virus particle), 1x10 7 to 1x10 13 VP, 1x10 8 to 1x10 12 VP, or 1x10 9 to 1x10 11 VP.
- virus 1x10 6 to 1x10 14 VP Virus particle
- 1x10 7 to 1x10 13 VP 1x10 8 to 1x10 12 VP
- 1x10 9 to 1x10 11 VP can be any virus 1x10 6 to 1x10 14 VP (Virus particle), 1x10 7 to 1x10 13 VP, 1x10 8 to 1x10 12 VP, or 1x10 9 to 1x10 11 VP.
- the cationic compound may be a cationic lipid or a cationic polymer, and more specifically, a cationic lipid.
- the cationic lipid is N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-( 1-(2,3-dioleoyloxy)propyl-N,N,N-trimethylammonium chloride (DOTAP), N,N-dimethyl-(2,3-dioleoyloxy)propylamine (DODMA), N ,N,N-Trimethyl-(2,3-dioleoyloxy)propylamine (DOTMA), 1,2-Diacyl-3-trimethylammonium-propane (TAP), 1,2-Diacyl-3-dimethyl Ammonium-propane (DAP), 3beta-[N-(N',N',N'-trimethylaminoethane)carbamoyl]cholesterol (TC-cholesterol), 3beta-
- a cationic lipid In the case of using such a cationic lipid, it is preferable to use less polycationic lipid having a high cation density in the molecule in order to reduce toxicity induced from the cationic lipid, and more specifically, it is possible to represent cations in aqueous solution per molecule. It is preferable to use a cationic lipid having one functional group.
- the cationic lipid is 3beta-[N-(N',N',N'-trimethylaminoethane)carbamoyl]cholesterol (TC-cholesterol), 3beta[N-( N',N'-dimethylaminoethane)carbamoyl]cholesterol (DC-cholesterol), 3beta[N-(N'-monomethylaminoethane)carbamoyl]cholesterol (MC-cholesterol), 3beta[N-( Aminoethane)carbamoyl]cholesterol (AC-cholesterol), N-(1-(2,3-dioleoyloxy)propyl-N,N,N-trimethylammonium chloride (DOTAP), N,N-dimethyl-( 2,3-dioleoyloxy)propylamine (DODMA), and N,N,N-trimethyl-(2,3-
- the cationic polymer is chitosan (chitosan), glycol chitosan (glycol chitosan), protamine (protamine), polylysine (polylysine), polyarginine (polyarginine), polyamidoamine (PAMAM), Polyethylenimine, dextran, hyaluronic acid, albumin, high molecular weight polyethyleneimine (PEI), polyamine and polyvinylamine (PVAm) may be selected from the group consisting of, and more specifically As the example, it may be at least one selected from the group consisting of polyethyleneimine (PEI), polyamine, and polyvinylamine (PVAm).
- PEI polyethyleneimine
- PVAm polyvinylamine
- the cationic lipid may be a cationic lipid of Formula 1 below:
- n and m are each independently 0 to 12, 2 ⁇ n + m ⁇ 12,
- a and b are each independently 1 to 6,
- R 1 and R 2 are each independently selected from the group consisting of saturated and unsaturated hydrocarbon groups having 11 to 25 carbon atoms.
- n and m are each independently 1 to 9, and 2 ⁇ n+m ⁇ 10.
- a and b may each independently be 2 to 4.
- R 1 and R 2 are each independently, lauryl, myristyl, palmityl, stearyl, arachidyl, be Hennyl, lignoceryl, cerotyl, myristoleyl, palmitoleyl, sapienyl, oleyl, linoleyl ( linoleyl), arachidonyl, eicosapentaenyl, erucyl, docosahexaenyl, and cerotyl may be selected from the group consisting of.
- the cationic lipid is 1,6-dioleoyltriethylenetetramide (N,N'-((ethane-1,2-diylbis(azanediyl))bis(ethane-2,1-diyl) ) dioleamide), 1,8-dilinoleoyltetraethylenepentamide ((9Z,9'Z,12Z,12'Z)-N,N'-(((azanediylbis(ethane-2,1-diyl)) bis(azanediyl))bis(ethane-2,1-diyl))bis(octadeca-9,12-dienamide)), 1,4-dimyristoleoyldiethylenetriamide ((9Z,9'Z)-N ,N'-(azanediylbis(ethane-2,1-diyl))bis(tetradec-9-enamide)), 1,10
- the content of the cationic compound in the drug-containing nanoparticles prepared by the kit of the present invention is, based on 1 part by weight of the drug, for example, 25 parts by weight or less, 20 parts by weight or less, 18 parts by weight or less, 15 parts by weight or less , 12 parts by weight or less, 10 parts by weight or less, or 8 parts by weight or less, and also 1 part by weight or more, 1.5 parts by weight or more, 2 parts by weight or more, 2.5 parts by weight or more, 3 parts by weight or more, or 3.5 parts by weight or more.
- the content of the cationic compound in the drug-containing nanoparticles is, based on 1 part by weight of the drug, 1 to 25 parts by weight, 1.5 to 10 parts by weight, 2 to 15 parts by weight, 2.5 to 10 parts by weight, or 3 to 8 parts by weight.
- the content of the cationic compound is 1 ⁇ g or more, 5 ⁇ g or more, 10 ⁇ g or more, 15 ⁇ g or more, or 18 ⁇ g or more, based on 1x10 10 VP of the virus, and 150 ⁇ g or less, 100 ⁇ g or less, 50 ⁇ g or less, or 30 ⁇ g or less, for example, 1 ⁇ g to 150 ⁇ g, 5 ⁇ g to 100 ⁇ g, 10 ⁇ g to 50 ⁇ g, 15 ⁇ g to 30 ⁇ g. If the content of the cationic compound in the drug-containing nanoparticles is less than the above range, the drug may not be stably included in the nanoparticles. There is a risk that the loss rate may increase during filter sterilization.
- the cationic compound and the nucleic acid bind through electrostatic interaction.
- the ratio of the charge amount of the nucleic acid (P) and the cationic compound (N) is 0.5 or more, 1 or more, 2 or more , or 3.5 or more, and may be 100 or less, 50 or less, 20 or less, for example, 0.5 to 100, 1 to 50, 2 to 20, 5 to 15, or 7 to 12.
- the ratio (N/P) When the ratio (N/P) is less than the above range, a sufficient amount of nucleic acid may not be included in the drug-containing nanoparticles, whereas when the ratio (N/P) exceeds the above range, there is a risk of causing toxicity there is In addition, the N/P value may play an important role in the specific expression of the active ingredient in the spleen.
- the kit for preparing drug-containing nanoparticles of the present invention does not include an amphiphilic polymer (eg, an amphiphilic block copolymer). That is, neither of the first chamber and the second chamber contains the amphiphilic polymer.
- an amphiphilic polymer eg, an amphiphilic block copolymer
- the kit for preparing the drug-containing nanoparticles of the present invention is one selected from the group consisting of a hydrophilic A block (eg, polyalkylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, polyacrylamide and derivatives thereof) or more) and a hydrophobic B block (eg, at least one selected from the group consisting of monomethoxypolyethylene glycol, monoacetoxypolyethylene glycol, polyethylene glycol, a copolymer of polyethylene and propylene glycol, and polyvinylpyrrolidone) It does not contain an amphiphilic block copolymer which is an A-B type block copolymer.
- a hydrophilic A block eg, polyalkylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, polyacrylamide and derivatives thereof
- a hydrophobic B block eg, at least one selected from the group consisting of monomethoxypolyethylene glycol, monoacetoxypoly
- the polylactate in the drug-containing nanoparticles prepared by the kit of the present invention is distributed in the core of the nanoparticles to strengthen the hydrophobicity of the core to stabilize the nanoparticles and at the same time to stabilize the reticuloendothelial system (RES) is effectively avoided. That is, the carboxylate anion of polylactic acid binds to the cationic compound more effectively than polylactic acid and reduces the surface potential of the polymer nanoparticles. It is less captured by the endothelial system, and thus has an advantage in that the drug delivery efficiency to a target site (eg, cancer cells, inflammatory cells, etc.) is excellent.
- a target site eg, cancer cells, inflammatory cells, etc.
- the polylactic acid salt may have a number average molecular weight of 500 to 50,000 Daltons, and more specifically, 1,000 to 10,000 Daltons. If the number average molecular weight of the polylactate is less than 500 Daltons, the hydrophobicity may be too low to exist in the core (inner wall) of the nanoparticles, and if it exceeds 50,000 Daltons, there may be a problem in that the nanoparticles become large.
- the terminal opposite to the metal carboxylate (eg, sodium carboxylate) among the ends of the polylactic acid salt (eg, sodium polylactate) is hydroxy, acetoxy, benzoyloxy, decanoyloxy , may be substituted with one selected from the group consisting of palmitoyloxy and alkoxy having 1 to 2 carbon atoms.
- A is -COO-CHZ-;
- B is -COO-CHY-, -COO-CH 2 CH 2 CH 2 CH 2 CH 2 - or -COO-CH 2 CH 2 OCH 2 -;
- R is a hydrogen atom or an acetyl, benzoyl, decanoyl, palmitoyl, methyl, or ethyl group;
- Z and Y are each a hydrogen atom, or a methyl or phenyl group;
- M is Na, K, or Li;
- n is an integer from 1 to 30;
- m is an integer from 0 to 20;
- X is a methyl group
- Y' is a hydrogen atom or a phenyl group
- p is an integer from 0 to 25
- q is an integer from 0 to 25, with the proviso that p+q is an integer from 5 to 25
- R is a hydrogen atom or an acetyl, benzoyl, decanoyl, palmitoyl, methyl or ethyl group
- M is Na, K, or Li
- Z is a hydrogen atom, a methyl or phenyl group
- W-M' is or ego
- PAD is D,L-polylactic acid, D-polylactic acid, polymandelic acid, copolymer of D,L-lactic acid and glycolic acid, copolymer of D,L-lactic acid and mandelic acid, D,L-lactic acid and copolymers of caprolactone and copolymers of D,L-lactic acid and 1,4-dioxan-2-one
- R is a hydrogen atom or an acetyl, benzoyl, decanoyl, palmitoyl, methyl or ethyl group
- M is independently Na, K, or Li
- S is ego;
- L is -NR 1 - or -0-, wherein R 1 is a hydrogen atom or C 1-10 alkyl;
- Q is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH 2 CH 2 CH 2 CH 3 , or CH 2 C 6 H 5 ;
- a is an integer from 0 to 4;
- b is an integer from 1 to 10;
- M is Na, K, or Li;
- PAD is D,L-polylactic acid, D-polylactic acid, polymandelic acid, copolymer of D,L-lactic acid and glycolic acid, copolymer of D,L-lactic acid and mandelic acid, D,L-lactic acid and at least one selected from the group consisting of a copolymer of caprolactone, and a copolymer of D,L-lactic acid and 1,4-dioxan-2-one;
- R' is -PAD-OC(O)-CH 2 CH 2 -C(O)-OM, wherein PAD is D,L-polylactic acid, D-polylactic acid, polymandelic acid, D ,L-lactic acid and glycolic acid copolymer, D,L-lactic acid and mandelic acid copolymer, D,L-lactic acid and caprolactone copolymer, D,L-lactic acid and 1,4-dioxane-2 -one is selected from the group consisting of copolymers, M is Na, K, or Li; a is an integer from 1 to 4;
- X and X' are independently hydrogen, alkyl having 1 to 10 carbons, or aryl having 6 to 20 carbons; Y and Z are independently Na, K, or Li; m and n are independently integers from 0 to 95, provided that 5 ⁇ m + n ⁇ 100; a and b are independently integers from 1 to 6; R is -(CH 2 ) k -, divalent alkenyl having 2 to 10 carbon atoms, divalent aryl having 6 to 20 carbon atoms, or a combination thereof, where k is 0 to 10 is the integer of
- the polylactic acid salt may be a compound of Formula 2 or Formula 3 above.
- the nanoparticles in the first chamber may further include a confluent lipid.
- the amount of the fusing lipid contained in the nanoparticles in the first chamber is 0.01 to 50% by weight, more specifically, based on the total weight of the drug-containing nanoparticles prepared by the kit of the present invention. It may be 0.1 to 10% by weight.
- the fusible lipid binds by hydrophobic interaction with the cationic compound to form a nanoparticle structure.
- the fusible lipid may be one or a combination of two or more selected from the group consisting of phospholipids, cholesterol, and tocopherol.
- the phospholipid may be at least one selected from the group consisting of phosphatidylethanolamin (PE), phosphatidylcholine (PC) and phosphatidic acid.
- the phosphatidylethanolamine (phosphatidylethanolamin, PE), phosphatidylcholine (PC) and phosphatidic acid may be combined with one or two C10-24 fatty acids.
- the cholesterol and tocopherol include analogs, derivatives, and metabolites of cholesterol and tocopherol, respectively.
- the fusible lipid is dilauroyl phosphatidylethanolamine (dilauroyl phosphatidylethanolamine), dimyristoyl phosphatidylethanolamine (dimyristoyl phosphatidylethanolamine), dipalmitoyl phosphatidylethanolamine (dipalmitoyl phosphatidylethanolamine), distearoyl Ethanolamine (distearoyl phosphatidylethanolamine), dioleoyl phosphatidylethanolamine (DOPE), dipalmitoleoyl phosphoethanolamine (1,2-dipalmitoleoyl-sn-glycero-3-phosphoethanolamine, DPPE), dilinoleo yl phosphatidylethanolamine (dilinoleoyl phosphatidylethanolamine), 1-palmitoyl-2-oleoyl phosphatidylethanolamine (1-palmitoyl-2-oleoyl phosphati
- the fusible lipid is dioleoyl phosphatidylethanolamine (DOPE), dipalmitoleoyl phosphocholine (1,2-dipalmitoleoyl-sn-glycero-3-phosphocholine, DPPC), diol as leoyl phosphocholine (1,2-dioleoyl-sn-glycero-3-phosphocholine, DOPC) and dipalmitoleoyl-phosphoethanolamine (1,2-dipalmitoleoyl-sn-glycero-3-phosphoethanolamine, DPPE) It may be at least one selected from the group consisting of.
- DOPE dioleoyl phosphatidylethanolamine
- DOPC dipalmitoleoyl phosphocholine
- DOPC dipalmitoleoyl-phosphocholine
- DOPC dipalmitoleoyl-phosphocholine
- DOPC dipalmitoleoyl-phosphoethanolamine
- DPPE dipalmitoleo
- the content of the polylactate among the components in the drug-containing nanoparticles prepared by the kit of the present invention is 0.1 parts by weight or more, 0.2 parts by weight or more, based on 1 part by weight of the cationic compound; It may be 0.3 parts by weight or more, 0.4 parts by weight or more, or 0.5 parts by weight or more, and also 15 parts by weight or less, 10 parts by weight or less, 9 parts by weight or less, 8 parts by weight or less, 7 parts by weight or less, 6 parts by weight or less, 5 parts by weight or less. parts by weight or less, 4 parts by weight or less, or 3 parts by weight or less.
- the amount of the polylactic acid salt may be 0.1 to 15 parts by weight, more specifically 0.2 to 10 parts by weight, and even more specifically 0.3 to 5 parts by weight, based on 1 part by weight of the cationic compound. and, more specifically, may be 0.5 to 3 parts by weight.
- the content of the polylactic acid salt may be adjusted according to the drug within the above range.
- the content of the polylactic acid salt when the drug is a virus, may be 3 to 15 parts by weight based on 1 part by weight of the cationic compound, and in another embodiment, when the drug is a nucleic acid, the polylactic acid The content of the salt may be 0.2 to 10 parts by weight, 0.3 to 5 parts by weight, or 0.5 to 3 parts by weight based on 1 part by weight of the cationic compound.
- the first chamber and/or the second chamber may further include an aqueous solution, a water-miscible organic solvent, or a combination thereof.
- aqueous solution may be used in the same sense as an aqueous solution, for example, may refer to water, sterile purified water, buffer solution, injection solution, etc., may be a buffer solution further containing an organic acid.
- the aqueous solution may be, for example, a citric acid buffer, a PBS buffer, and the like, but is not limited thereto.
- the "water-miscible organic solvent” may be a C1 to C4 lower alcohol, acetone, acetonitrile, a water mixture thereof, or a mixture thereof, but is not limited thereto.
- the cationic compound and the polylactic acid salt may be used in the preparation of nanoparticles in the form of a solution that has been filtered one or more times. More specifically, the filtration may be performed using a hydrophilic filter.
- a hydrophilic filter for example, nylon, mixed cellulose ester (MCE), polyethylsulfone (PES), polyvinylidene difluoridem PVDF), cellulose acetate (cellulose acetate, CA) ), polytetrafluoroethylene (PTFE), and mixtures thereof.
- MCE mixed cellulose ester
- PES polyethylsulfone
- PVDF polyvinylidene difluoridem PVDF
- cellulose acetate cellulose acetate
- CA polytetrafluoroethylene
- PTFE polytetrafluoroethylene
- the second chamber may further include a stabilizing agent suitable for improving the stability of the drug.
- the stabilizer may further include a pH adjuster, an inorganic salt, a saccharide, a surfactant, a chelating agent, and the like, but is not limited thereto.
- the “saccharide” may refer to monosaccharides, disaccharides, sugar alcohols that are reducing sugars thereof, polymers of single or mixed polysaccharides, and the like, and the polysaccharides may refer to three or more saccharides.
- the monosaccharides include, for example, mannose, glucose, arabinose, fructose, galactose, and the like;
- Examples of the disaccharide include sucrose, trehalose, maltose, lactose, cellobiose, gentiobiose, isomaltose, melibose, and the like;
- the sugar alcohol includes mannitol, sorbitol, xylitol, erythritol, maltitol, and the like;
- Examples of the polysaccharide include, but are not limited to, raffinose, dextran, starch, hydroxyethyl starch, cyclodextrin, cellulose, hetastarch, and oligosaccharide.
- the “pH adjusting agent” may be Tris, glycine, histidine, glutamate, succinate, phosphate, acetate, aspartate or a combination thereof
- the “surfactant” may be sodium lauryl sulfate, dioctyl sodium Sulfosuccinate, dioctyl sodium sulfonate, chenodeoxycholic acid, N-lauroyl sarcosine sodium salt, lithium dodecyl sulfate, 1-octanesulfonic acid sodium salt, sodium cholate hydrate, sodium deoxycholate, glycode Sodium oxycholic acid salt, benzalkonium chloride, Triton X-100, Triton X-114, lauromacrogol 400, polyoxyl 40 stearate, polysorbate 20, 40, 60, 65 and 80 Or it may be a combination thereof, but is not limited thereto.
- the “chelating agent” may be citric acid, polyphenolic acid, EDTA, DTPA, EDDHA, or a combination thereof, but is not limited thereto.
- the “inorganic salt” refers to a salt of a monovalent or divalent metal, and may be NaCl, KCl, MgCl 2 , CaCl 2 , MgSO 4 , CaSO 4 , CaCO 3 , MgCO 3 , or the like, but is not limited thereto.
- the second chamber may contain 5 to 15 mM Tris, 5 to 15 mM histidine, 50 to 90 mM NaCl, 2 to 8% sucrose (w/v), 0.5 to 1.5 mM MgCl 2 , 0.005 to 0.05% (w/v) PS-80, 0.05 to 0.15 mM EDTA, and 0.1 to 1.0% ethanol (v/v), and the pH may be 7.0 to 8.0.
- the second chamber is a PBS buffer, for example, PH 7.0 to pH 8.0, 2.0 to 3.5 mM KCl, 1.0 to 2.5 mM KH 2 PO 4 , 125 to 145 mM NaCl, and a solution comprising 7.5 to 9.5 mM Na 2 HPO 4 .
- the drug-containing nanoparticle preparation kit of the present invention comprises: the drug selected from nucleic acids, polypeptides, viruses, or a combination thereof; the cationic compound; the polylactate; menstruum; and at least one additive selected from a pH adjuster, an inorganic salt, a sugar, a surfactant, a chelating agent, or a combination thereof.
- the particle size of the drug-containing nanoparticles may be defined as a Z-average value, for example, 800 nm or less, 600 nm or less, 500 nm or less, or 400 nm or less, and also 100 nm or more, 150 nm or greater, 200 nm or greater, or 250 nm or greater.
- the particle size of the drug-containing nanoparticles, defined as the Z-average value may be, for example, 100 to 800 nm, 100 to 600 nm, 100 to 500 nm, or 100 to 400 nm. .
- the "chamber” is suitable for containing a material of nanoparticles or a solvent containing the same, and includes glass, plastic, paper, pack, etc., but is not limited thereto.
- a nanoparticle composition in the first chamber was prepared using 1,6-dioleoyl triethylenetetramide (dioTETA) and polylactate (PLANa).
- dioTETA 1,6-dioleoyl triethylenetetramide
- PLANa polylactate
- dioTETA was dissolved in 20 mM sodium acetate buffer to prepare a dioTETA solution with a concentration of 5 mg/mL
- PLANa was dissolved in water to prepare a PLANa solution with a concentration of 10 mg/mL, and then each solution was treated with a 0.22 ⁇ m hydrophilic filter. After filtration and sterilization, each solution was taken and mixed so that the dioTETA/PLANa mole ratio was 1, and the final volume was adjusted with water.
- cationic lipid SM102
- distearoylphosphatidylcholine Distearoylphosphatidylcholine, DSPC
- cholesterol 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (1,2-Dimyristoyl-rac-glycero) -3-methoxypolyethylene glycol-2000 and DMG-PEG 2000
- SM102 distearoylphosphatidylcholine
- DSPC disearoylphosphatidylcholine
- cholesterol 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (1,2-Dimyristoyl-rac-glycero) -3-methoxypolyethylene glycol-2000 and DMG-PEG 2000
- GFP mRNA was diluted with PBS to prepare an mRNA solution in the second chamber.
- mRNA- 5 ⁇ g of mRNA was used in the preparation of nanoparticles.
- the prepared nanoparticle composition in the first chamber and the mRNA solution in the second chamber were mixed by stirring (vortexing) to prepare mRNA-containing nanoparticles.
- agarose gel electrophoresis was performed to confirm whether the nanoparticles and mRNA were normally combined. Examples and Comparative Examples After simply mixing the nanoparticle composition in the first chamber and the mRNA solution in the second chamber, a volume corresponding to 400 ng of mRNA was taken and mixed with the loading dye. Then, it was taken on a 1% agarose gel, electrophoresed at an appropriate voltage and time, and then the image of the mRNA band was observed through a UV transilluminator device. In this case, Dyne Gel Safe Red Kit (Dyne Bio) was used as a nucleic acid staining reagent.
- FIG. 1 The measurement results are shown in FIG. 1 .
- the exposed mRNA band hardly appeared due to the high binding force between the nanoparticles and the mRNA in the first chamber, whereas in the Comparative Example, the nanoparticles in the first chamber did not bind to the mRNA, so that most of the mRNA was observed as such. That is, in Examples, nanoparticles containing mRNA were successfully prepared, but in Comparative Examples, this was not the case.
- mRNA-containing nanoparticles could be prepared even in a non-kit method (ie, simple mixing) using the components used in each of the Examples and Comparative Examples. That is, after mixing all the components used for the preparation of the first chamber and the second chamber in each of the Examples and Comparative Examples at once, agarose gel electrophoresis was performed in the same manner as above.
- FIG. 2 The measurement results are shown in FIG. 2 .
- the preparation of mRNA-containing nanoparticles is possible by simple mixing of all components in a non-kit method, but the kit method of the present invention (ie, the nanoparticle composition in the first chamber and the second It was confirmed that it was impossible to prepare each mRNA solution in the chamber and then mix).
- a nanoparticle composition in the first chamber was prepared using 1,6-dioleoyl triethylenetetramide (dioTETA) and polylactate (PLANa).
- dioTETA 1,6-dioleoyl triethylenetetramide
- PLANa polylactate
- dioTETA was dissolved in 20 mM sodium acetate buffer to prepare a dioTETA solution with a concentration of 5 mg/mL
- PLANa was dissolved in water to prepare a PLANa solution with a concentration of 10 mg/mL, and then each solution was treated with a 0.22 ⁇ m hydrophilic filter. was filtered and sterilized.
- a sucrose solution of 400 mg/mL concentration was prepared by dissolving sucrose in water. Each solution was taken and mixed so that the dioTETA/PLANa mole ratio was 1, and the final volume was adjusted with water. At this time, 10% of the final volume was added with sucrose solution.
- GFP mRNA was diluted with PBS to prepare an mRNA solution in the second chamber.
- mRNA- 5 ⁇ g of mRNA was used in the preparation of nanoparticles.
- the prepared nanoparticle composition in the first chamber was stored frozen at ultra-low temperature for 1 to 4 days, thawed at room temperature, and mixed with the mRNA solution in the second chamber by vortexing to prepare mRNA-containing nanoparticles ( Example). Meanwhile, the mRNA-containing nanoparticles prepared by the non-kit method (simple mixing) were frozen and thawed at room temperature after 1 to 4 days (Comparative Example). In addition, the nanoparticles (not containing mRNA) prepared in the first chamber were stored frozen at ultra-low temperature for 1 to 4 days, and then thawed at room temperature was used as a control.
- the particle size of the nanoparticles in the first chamber thawed at room temperature after freezing for 1 to 4 days was maintained similar to that before freezing (control group), and after freezing for 1 to 4 days, thawed at room temperature for 1 to 4 days
- the particle size of the mRNA-containing nanoparticles obtained by mixing the nanoparticles in the chamber with the mRNA in the second chamber was maintained similar to that of the mRNA-containing nanoparticles obtained using the nanoparticles before freezing (Example).
- nanoparticles frozen for 1 to 4 days in a state containing mRNA increased in particle size after thawing and particle precipitation was observed (Comparative Example).
- the size of nanoparticles can be maintained similar to that before storage, and mRNA-containing nanoparticles can be prepared by simply mixing them with a drug (eg, mRNA), so that eventually mRNA - It can greatly improve the storage stability of the containing nanoparticles.
- a drug eg, mRNA
- a nanoparticle composition in the first chamber was prepared using 1,6-dioleoyl triethylenetetramide (dioTETA) and polylactate (PLANa).
- dioTETA 1,6-dioleoyl triethylenetetramide
- PLANa polylactate
- dioTETA was dissolved in 20 mM sodium acetate buffer to prepare a dioTETA solution with a concentration of 5 mg/mL
- PLANa was dissolved in water to prepare a PLANa solution with a concentration of 10 mg/mL
- each solution was treated with a 0.22 ⁇ m hydrophilic filter. to filter and sterilize, and each solution was mixed so as to have the ratio shown in Table 2 below.
- a PLANa/mPEG-PLA solution having a concentration of 10 mg/mL was prepared by dissolving polylactate (PLANa) and monomethoxypolyethylene glycol-polylactide copolymer (mPEG-PLA) in water, and then each The solution was filtered and sterilized using a 0.22 ⁇ m hydrophilic filter, and each solution was mixed in the ratio shown in Table 2 below to prepare a nanoparticle composition in the first chamber.
- PLANa polylactate
- mPEG-PLA monomethoxypolyethylene glycol-polylactide copolymer
- a second chamber mRNA solution was prepared by diluting luciferase mRNA with PBS. mRNA- 5 ⁇ g of mRNA was used in the preparation of nanoparticles.
- the prepared nanoparticle composition in the first chamber and the mRNA solution in the second chamber were mixed by stirring (vortexing) to prepare mRNA-containing nanoparticles.
- the transfection efficiency was measured by treating the HepG2 (human liver cancer) cell line.
- Examples 1 to 4 and Comparative Examples 1 to 4 mRNA-containing nanoparticles were dispensed in an amount corresponding to 250 ng mRNA per well to HepG2 cells seeded in a 96 well plate. After 15 to 24 hours, the amount of luciferase (luminescence, RLU) expressed in the cells was measured using the ONE-GloTM Luciferase Assay System (Promega).
- TransIT® Transfection Kit (Mirus Bio), which is a commonly used transfection reagent, was used. The measurement results are shown in Table 3 below.
- dioTETA 1,6-Dioleoyl triethylenetetramide
- PLANa polylactate
- dioTETA was dissolved in 20 mM sodium acetate buffer to prepare a dioTETA solution with a concentration of 5 mg/mL
- PLANa was dissolved in water to prepare a PLANa solution with a concentration of 10 mg/mL
- each solution was treated with a 0.22 ⁇ m hydrophilic filter. was filtered and sterilized.
- Each solution was taken and mixed so that the dioTETA/PLANa mole ratio was 1, and the final volume was adjusted with water.
- mRNA human Trp2, murine Trp2, OVA mRNA
- PBS PBS
- 10 ⁇ g of mRNA was used for preparing mRNA-nanoparticles.
- mRNA-containing nanoparticles were prepared.
- DLS Dynamic Light Scattering
- mRNA-containing nanoparticles of similar size were formed in all three kinds of mRNA within the range of particle size of 330 to 370 nm and surface potential of -10 to -20 mV.
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (9)
- 양이온성 화합물 및 폴리락트산염을 포함하는 나노입자를 포함하는 제1 챔버; 및핵산, 폴리펩티드, 바이러스 또는 이들의 조합으로부터 선택된 유효성분인 약물을 포함하는 제2 챔버;를 포함하며,양친성 고분자를 포함하지 않는,약물-함유 나노입자 제조용 키트.
- 제1항에 있어서, 상기 약물-함유 나노입자는 상기 약물을 세포 내로 전달하기 위한 것인, 약물-함유 나노입자 제조용 키트.
- 제1항에 있어서, 상기 제1 챔버 및 제2 챔버로 이루어진 군 중에서 선택된 하나 이상은 추가의 용매를 더 포함하는 것인, 약물-함유 나노입자 제조용 키트.
- 제3항에 있어서, 상기 용매는 수성 용매, 수혼화성 용매 또는 이의 혼합물인, 약물-함유 나노입자 제조용 키트.
- 제1항에 있어서, 상기 제2 챔버는 pH 조절제, 무기염, 당류, 계면활성제, 킬레이트제 또는 이들의 조합을 더 포함하는 것인, 약물-함유 나노입자 제조용 키트.
- 제1항에 있어서, 핵산, 폴리펩티드, 바이러스 또는 이들의 조합으로부터 선택된 유효성분인 약물; 양이온성 화합물; 폴리락트산염; 용매; 및 pH 조절제, 무기염, 당류, 계면활성제, 킬레이트제 또는 이들의 조합으로부터 선택되는 하나 이상의 첨가제;로 이루어진 것인, 약물-함유 나노입자 제조용 키트.
- 제1항에 있어서, 상기 폴리락트산염의 양은 상기 양이온성 화합물 1 중량부를 기준으로 0.1 내지 15 중량부인, 약물-함유 나노입자 제조용 키트.
- 제1항에 있어서, 상기 폴리락트산염의 양은 상기 양이온성 화합물 1 중량부를 기준으로 0.5 내지 3 중량부인, 약물-함유 나노입자 제조용 키트.
- 제1항에 있어서, 상기 양이온성 화합물 및 폴리락트산염은 1회 이상 여과된 용액의 형태로 나노입자의 제조에 사용된, 약물-함유 나노입자 제조용 키트.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112023022548A BR112023022548A2 (pt) | 2021-04-30 | 2022-04-29 | Kit para preparar nanopartículas contendo fármaco |
JP2023566825A JP2024517766A (ja) | 2021-04-30 | 2022-04-29 | 薬物を含有し、両親媒性高分子を含まないナノ粒子製造用キット |
EP22796206.5A EP4331575A1 (en) | 2021-04-30 | 2022-04-29 | Kit for preparing nanoparticles containing drug and comprising no amphiphilic polymers |
AU2022266457A AU2022266457A1 (en) | 2021-04-30 | 2022-04-29 | Kit for preparing nanoparticles containing drug and comprising no amphiphilic polymers |
CN202280035021.XA CN117377467A (zh) | 2021-04-30 | 2022-04-29 | 用于制备含有药物且不含两亲聚合物的纳米颗粒的试剂盒 |
CA3216946A CA3216946A1 (en) | 2021-04-30 | 2022-04-29 | Kit for preparing nanoparticles containing drug and comprising no amphiphilic polymers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210056374 | 2021-04-30 | ||
KR10-2021-0056374 | 2021-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022231374A1 true WO2022231374A1 (ko) | 2022-11-03 |
Family
ID=83848361
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/006174 WO2022231374A1 (ko) | 2021-04-30 | 2022-04-29 | 약물을 함유하고 양친성 고분자를 포함하지 않는 나노입자 제조용 키트 |
PCT/KR2022/006177 WO2022231375A1 (ko) | 2021-04-30 | 2022-04-29 | 양친성 고분자를 함유하지 않는 나노입자를 포함하는 약물전달용 조성물 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/006177 WO2022231375A1 (ko) | 2021-04-30 | 2022-04-29 | 양친성 고분자를 함유하지 않는 나노입자를 포함하는 약물전달용 조성물 |
Country Status (8)
Country | Link |
---|---|
EP (2) | EP4331575A1 (ko) |
JP (2) | JP2024515387A (ko) |
KR (2) | KR20220149460A (ko) |
CN (2) | CN117377467A (ko) |
AU (2) | AU2022266457A1 (ko) |
BR (2) | BR112023022543A2 (ko) |
CA (2) | CA3216946A1 (ko) |
WO (2) | WO2022231374A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110077818A (ko) * | 2009-12-30 | 2011-07-07 | 주식회사 삼양사 | 폴리락트산을 포함하는 음이온성 약물 전달용 조성물 및 그 제조 방법 |
KR20170032858A (ko) * | 2015-09-15 | 2017-03-23 | 주식회사 삼양바이오팜 | 음이온성 약물 함유 약제학적 조성물 및 그 제조방법 |
WO2018220553A1 (en) * | 2017-05-30 | 2018-12-06 | Glaxosmithkline Biologicals Sa | Methods for manufacturing a liposome encapsulated rna |
KR20190127277A (ko) * | 2018-05-04 | 2019-11-13 | 주식회사 삼양바이오팜 | mRNA 전달용 고분자 나노입자 조성물 및 그 제조방법 |
KR20200016806A (ko) * | 2018-08-07 | 2020-02-17 | 주식회사 삼양바이오팜 | 바이러스 전달용 고분자 나노입자 조성물 및 그의 제조방법 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102259513B1 (ko) * | 2017-11-16 | 2021-06-02 | 주식회사 삼양홀딩스 | 음이온성 약물 함유 약제학적 조성물의 동결건조 조성물 및 방법 |
-
2022
- 2022-04-29 AU AU2022266457A patent/AU2022266457A1/en active Pending
- 2022-04-29 JP JP2023566826A patent/JP2024515387A/ja active Pending
- 2022-04-29 CA CA3216946A patent/CA3216946A1/en active Pending
- 2022-04-29 BR BR112023022543A patent/BR112023022543A2/pt unknown
- 2022-04-29 CN CN202280035021.XA patent/CN117377467A/zh active Pending
- 2022-04-29 KR KR1020220053219A patent/KR20220149460A/ko active Search and Examination
- 2022-04-29 AU AU2022266501A patent/AU2022266501A1/en active Pending
- 2022-04-29 WO PCT/KR2022/006174 patent/WO2022231374A1/ko active Application Filing
- 2022-04-29 EP EP22796206.5A patent/EP4331575A1/en active Pending
- 2022-04-29 BR BR112023022548A patent/BR112023022548A2/pt unknown
- 2022-04-29 EP EP22796207.3A patent/EP4331576A1/en active Pending
- 2022-04-29 JP JP2023566825A patent/JP2024517766A/ja active Pending
- 2022-04-29 CA CA3216941A patent/CA3216941A1/en active Pending
- 2022-04-29 WO PCT/KR2022/006177 patent/WO2022231375A1/ko active Application Filing
- 2022-04-29 KR KR1020220053220A patent/KR20220149461A/ko active Search and Examination
- 2022-04-29 CN CN202280032079.9A patent/CN117241791A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110077818A (ko) * | 2009-12-30 | 2011-07-07 | 주식회사 삼양사 | 폴리락트산을 포함하는 음이온성 약물 전달용 조성물 및 그 제조 방법 |
KR20170032858A (ko) * | 2015-09-15 | 2017-03-23 | 주식회사 삼양바이오팜 | 음이온성 약물 함유 약제학적 조성물 및 그 제조방법 |
WO2018220553A1 (en) * | 2017-05-30 | 2018-12-06 | Glaxosmithkline Biologicals Sa | Methods for manufacturing a liposome encapsulated rna |
KR20190127277A (ko) * | 2018-05-04 | 2019-11-13 | 주식회사 삼양바이오팜 | mRNA 전달용 고분자 나노입자 조성물 및 그 제조방법 |
KR20200016806A (ko) * | 2018-08-07 | 2020-02-17 | 주식회사 삼양바이오팜 | 바이러스 전달용 고분자 나노입자 조성물 및 그의 제조방법 |
Non-Patent Citations (2)
Title |
---|
DE PAULA DBENTLEY MVMAHATO RI: "Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting", RNA, vol. 13, 2007, pages 431 - 56 |
GARY DJPURI NWON YY: "Polymer-based siRNA delivery: Perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery", J CONTROL RELEASE, vol. 121, 2007, pages 64 - 73, XP022179907, DOI: 10.1016/j.jconrel.2007.05.021 |
Also Published As
Publication number | Publication date |
---|---|
JP2024515387A (ja) | 2024-04-09 |
EP4331575A1 (en) | 2024-03-06 |
AU2022266501A1 (en) | 2023-11-16 |
AU2022266457A1 (en) | 2023-11-16 |
BR112023022548A2 (pt) | 2024-01-02 |
KR20220149460A (ko) | 2022-11-08 |
CA3216946A1 (en) | 2022-11-03 |
CA3216941A1 (en) | 2022-11-03 |
JP2024517766A (ja) | 2024-04-23 |
WO2022231375A1 (ko) | 2022-11-03 |
EP4331576A1 (en) | 2024-03-06 |
BR112023022543A2 (pt) | 2024-01-23 |
CN117241791A (zh) | 2023-12-15 |
CN117377467A (zh) | 2024-01-09 |
KR20220149461A (ko) | 2022-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021125805A1 (ko) | 폴리락트산염을 포함하는 약물전달용 나노입자 조성물 제조용 키트 | |
WO2019212288A1 (ko) | Messenger rna 전달용 고분자 나노입자 조성물 및 그 제조방법 | |
US9962339B2 (en) | Stabilized assembled nanostructures for delivery of encapsulated agents | |
WO2022231374A1 (ko) | 약물을 함유하고 양친성 고분자를 포함하지 않는 나노입자 제조용 키트 | |
WO2020032581A1 (ko) | 바이러스 전달용 고분자 나노입자 조성물 및 그의 제조방법 | |
WO2024053862A1 (ko) | 약물 함유 나노입자 제조용 키트 및 약물전달용 나노입자 조성물 | |
US20210196836A1 (en) | Formulation of nanostructured gels for increased agent loading and adhesion | |
WO2019098691A2 (ko) | 음이온성 약물 함유 약제학적 조성물의 동결건조 조성물 및 방법 | |
WO2019093802A2 (ko) | 음이온성 약물 전달용 지질 나노입자의 동결건조 조성물 및 방법 | |
WO2021101265A1 (ko) | 약물전달용 나노입자 조성물 제조용 키트 | |
WO2023121388A1 (ko) | 약물의 폐 전달용 나노입자 조성물 | |
CA3241028A1 (en) | Lipids for drug delivery, nanoparticles comprising same, and composition for drug delivery comprising nanoparticles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22796206 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3216946 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023566825 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022266457 Country of ref document: AU Ref document number: AU2022266457 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 804982 Country of ref document: NZ |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023022548 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280035021.X Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2022266457 Country of ref document: AU Date of ref document: 20220429 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202347079814 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022796206 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022796206 Country of ref document: EP Effective date: 20231130 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112023022548 Country of ref document: BR Kind code of ref document: A2 Effective date: 20231027 |